Mayo Clinic

In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 12, 2024), Mayo Clinic reported 3 stock positions worth $2.9 million. Its top holding was iShares MSCI Acwi ETF (ACWI) at 71.5% of the portfolio, followed by Zentalis Pharmaceuticals (ZNTL, 22.2%) and Unity Biotechnology (UNBX, 6.3%). Compared with Q2 2024, it sold out of 1 and reduced 1. The biggest sale was an exit from Neuroone Med Technologies.

Most Recent 13F
Q3 2024
Location
Rochester, MN
CIK
0001318153
Portfolio Value
$2.9M (Q3 2024)
SEC Filing
0000912282-24-000766 ↗ filed Nov 12, 2024

Holdings Value

0$2.0M$4.0M$6.0M$8.0M Q1 2024: $6.1M Q1 2024 Q2 2024: $3.0M Q2 2024 Q3 2024: $2.9M $2.9M Q3 2024

Holdings 3 stocks · $2.9M
ACWI iShares MSCI Acwi ETF 71.52% 17,359 $2.1M No change
ZNTL Zentalis Pharmaceuticals Inc. 22.19% 175,000 $644K Reduce -6.5%
UNBX Unity Biotechnology Inc. 6.29% 124,081 $182K No change

Portfolio Sells Q2 2024 → Q3 2024
NEUROONE MED TECHNOLOGIES CO Sold out 0.00% −4.80
ZNTL Zentalis Pharmaceuticals Inc. Reduce -6.5% 22.19% −3.07

Portfolio Buys Q2 2024 → Q3 2024
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q3 2024 3$2.9MACWI, ZNTL, UNBX
Q2 2024 4$3.0MACWI, ZNTL, UNBX, NEUROONE MED TECHNOLOGIES CO
Q1 2024 5$6.1MZNTL, ACWI, CATX, NEUROONE MED TECHNOLOGIES CO, UNBX